Clinical Trials

Inclusion Criteria

• Signed informed written consent
• Patients are taking warfarin or apixaban chronically
• Patients are at risk of stroke or systemic embolism
• Patients have NVAF
• Patients will undergo CIED generator change
• Age 18-90
• Either gender
• All eligibility criteria must be met

Exclusion:

• Patient is critically ill, or in unstable condition
• Patient is at high risk for bleeding, HAS-BLED score ≥ 3
• Patient is required to take dual antiplatelet agents in addition to anticoagulant drug. (e.g. recent cardiac stent placement)
• Patients have mechanical cardiac valve or another condition other than NVAF that requires chronic anticoagulation
• Women of childbearing potential with positive pregnant test
• Bilirubin >2x upper limit of normal, in association with AST/ALT/ALP >3x upper limit normal
• Allergy to apixaban and warfarin
• Subjects requiring taking strong dual inhibitors of CYP3A4 and P-gp who already meet the criteria to take 2.5 mg apixaban
• Subjects requiring taking strong dual inducers of CYP3A4 and P-gp (.e.g., rifampin, carbamazepine, phenytoin, St. John's wort)
• Patients who take any investigational drugs within 30 days of enrolling in study.
• Prisoners or subjects who are involuntarily incarcerated.
• Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.